JW Pharmaceutical Presents Preclinical Results and Global Development Strategy for DDC-02, a Novel Therapeutic Candidate for Rare Neurodevelopmental Disorders
JW Pharmaceutical (KRX:001060) presented preclinical findings and its global development strategy for DDC-02, a therapeutic candidate for rare neurodevelopmental disorders, at the World Orphan Drug Congress USA 2026 (WODC USA 2026) in Boston, Massachusetts, from June 9 to 11.
